Download 477_2013_776_MOESM1_ESM - Springer Static Content Server

s-Table 1 Base-case estimates and the corresponding distributions for cost-effectiveness
analysis
Variables
Base-case estimate
Distribution Applied
Study-specific variables
Study 1-urban area (Taipei, Taiwan)
Proportion of vertical transmission
0.4118
Transition probabilities
Susceptible  Latent period
0.0343
Latent period  Active viral replication
0.6710
Active viral replication  Carrier
0.0465
Active viral replication  Recovery
0.0138
Carrier  Recovery
0.1126
Study 2-rural area (Pingtung, Taiwan)
Proportion of vertical transmission
0.8023
Transition probabilities
Susceptible  Latent period
0.0109
Latent period  Active viral replication
0.0698
Active viral replication  Carrier
0.0838
Active viral replication  Recovery
0.0236
Carrier  Recovery
0.1680
Common variables
Vaccine coverage rate
0.9033
Triangular(0.87,0.94)
Efficacy of prevention strategy for vertical transmission
Vaccine plus HBIG
0.9743
Beta(190,5)
Lamivudine
0.4868
Beta(18,107)/Beta(47/136)
Outcome of carrier (annual probability)
CAH
0.00308
Gamma(26, 8440)
Cirrhosis
0.00102
Gamma(8, 7815)
HCC
0.00208
Gamma(86, 41192.6)
Disease-specific death
0.00504
Gamma(553,109509)
Outcome of chronic active hepatitis (annual probability)
Cirrhosis
0.02625
Gamma(63,2400)
HCC
0.01131
Gamma(17, 1502.4)
Carrier
0.00608
Gamma(150, 24660)
Disease-specific death
0.03092
Gamma(9, 291)
Outcome of compensated cirrhosis (annual probability)
HCC
0.01507
Gamma(32,2123)
Decompensated cirrhosis
0.03908
Gamma(92.35,2363)
Disease-specific death
0.03487
Gamma(0.0888, 2.5473)
Outcome of decompensated cirrhosis (annual probability)
HCC
0.05
Disease-specific death
0.22234
Gamma(49.3, 221.72)
Outcome of HCC (annual probability)
Survive
0.078
Quality multipliers
Acute HBV infection
0.94
Triangular(0.901.00)
Carrier
1.00
Triangular(0.95,1.00)
Chronic active hepatitis
0.99
Triangular(0.90,1.00)
Compensated cirrhosis
0.80
Triangular(0.70,0.93)
Decompensated cirrhosis
0.60
Triangular(0.50,0.70)
Hepatocellular carcinoma
0.73
Triangular(0.50,0.80)
s-Table 2 Base-case estimate and distribution of cost $ (per year)
Variable
Base-case estimate
Distribution Applied
($/ per year)
Vaccine per birth
9
Triangular(1,17)
HBIG per birth
75
Triangular(27,110)
Lamivudine per pregnant woman
238
Triangular(71,400)
Acute infection
2385
Triangular(1380,3390)
Asymptomatic carrier
268
Triangular(200,300)
Chronic active hepatitis
3720
Triangular(2000,61440)
Compensated cirrhosis
33492
Triangular(2000,93910)
Decompensated cirrhosis
44862
Triangular(30000,93910)
HCC
57140
Triangular(31720,93910)
Indirect cost derived from capital income
Taiwan’s per capita income
17542
s-Figure 1 The detailed process for the temporal natural history of HBV infection
and the evolution of the sequale of HBV infection starting from asymptomatic
carrier until death from HCC
(a) Decision tree
Markov process
Markov process
Markov process
(b) Markov process
Natural history of HBV
infection
Sequale of chronic
HBV infection